Thus, targeting the functional interactions between Nav1.1 or 1.6 and disease-associated proteins represents a novel strategy for AD drug development—and could allow for improved tissue selectivity over agents that modulate Nav channels alone. The gene discussed is SCN1A; the disease is Alzheimer disease.